Valerie Sullivan was named the next president of digital health company etectRx. This isn’t Sullivan’s first time working with the company. She has worked with the company in a consulting role for the last year. Her previous work experience includes serving as the president of InVentiv Patient Access Solutions and as the VP and general manager of the patient service center at Pear Therapeutics.
“I’ve spent the last 15 years helping engage patients in their healthcare, and I am confident that our technology will define patient centricity in a new way,” Sullivan said in a statement. “This is a very exciting time in the digital health space. The roadmap for our technology is robust. It’s thrilling to have the opportunity to lead such a seasoned team as we work toward a future where there is a chip in every pill.”
Last week post-acute workforce management company IntelyCare made a slew of new hires. The list includes Robyn Lunsford, senior vice president of Workforce Growth and Retention, Prashanth Gali, senior vice president of engineering and Rachel Schiff, senior vice president of product management.
“We are the largest per-diem nursing tech company in the market, and will be a top-five per-diem provider by the end of 2020, which speaks to our unique position and approach in the space, as well as the heightened need for our market-leading technology and expertise,” John Shagoury, president and chief operating officer, said in a statement. “We are excited to have brought on new senior-level executives and to infuse our strategy with their deep expertise and passion for the work we do. Fueled by exciting growth, and recognition on the prestigious Inc. 5000 list, we are rolling up our sleeves and continuing to innovate new strategies and avenues for reimagining workforce management in the post-acute space.”
Diabetes focused startup DreaMed Diabetes named Ryan Hovey its new head of commercial strategy in the U.S. healthcare market.
Hovey is coming from his position as vice president of product at Optum’s Population Health Solutions business. He’s also worked in Optum’s Transplant Solutions business. At DreaMed, he will be working on expanding its insulin-management tech into clinics across the U.S.
“I’m glad to join DreaMed during such an exciting time,” Hovey said in a statement. “I’m especially looking forward to improving people’s lives by cultivating FDA-cleared, AI-based, clinically validated and remote personalized diabetes treatment optimization solutions in the U.S., further expanding on DreaMed’s impressive ascent.”
PixCell Medical, maker of a rapid diagnostic product, has appointed Dr. David Stein as the next chair of its board. Stein’s experience includes serving as the president of molecular diagnostics for Siemens Healthineers, CEO of Siemens Healthineers point of care business and head of strategy for the Diagnostics Division.
“PixCell Medical’s HemoScreen platform is the only hematology analyzer FDA-cleared for point-of-care use that can deliver the full 5-part differential CBC with comprehensive abnormal cell flagging within six minutes,” Stein said in a statement. “I have been in the diagnostics space and understand which products are poised to have the greatest impact. The HemoScreen, which leverages machine vision and PixCell’s patented Viscoelastic Focusing technology, provides rapid, lab-accurate results, changing how this essential diagnostic insight is delivered across the care continuum, from the ICU to primary care, oncology, and more. I am proud to be a part of this cutting-edge enterprise at this critical time in its development.”
Oncology-focused platform CancerIQ announced three new leadership position in its Integrated Products team. Lisa Glaspie, will serve as the new director of integrated products and Ashar Wasi will serve as integrated product specialist. Both Wasi and Glaspie came from Epic and have experience with HER integration services.
"To engage primary care, radiology, and cardiology in precision health – we need our content to be deeply embedded in the EHR systems they already use. We’re excited to bring Lisa and Ashar on board for their domain expertise with Epic, so fewer high-risk patients fall through the cracks,” Feyi Ayodele, CEO of CancerIQ, said in a statement.